169 related articles for article (PubMed ID: 37991299)
1. Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure.
Paul C
Indian J Ophthalmol; 2023 Dec; 71(12):3652-3657. PubMed ID: 37991299
[TBL] [Abstract][Full Text] [Related]
2. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
[TBL] [Abstract][Full Text] [Related]
3. A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy.
Holló G; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Oddone F;
Curr Med Res Opin; 2022 Jul; 38(7):1189-1201. PubMed ID: 35621005
[TBL] [Abstract][Full Text] [Related]
4. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
Oddone F; Tanga L; Kóthy P; Holló G;
Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A;
J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148
[No Abstract] [Full Text] [Related]
7. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
8. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
[TBL] [Abstract][Full Text] [Related]
10. Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma.
Rhee T; Kim J; Ha A
Korean J Ophthalmol; 2024 Jun; 38(3):221-226. PubMed ID: 38665112
[TBL] [Abstract][Full Text] [Related]
11. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes.
Ansari E; Chappiti S; Pavicic-Astalos J; Pinto-Bonilla JC; Riva I; Sacchi M; Saénz-Francés F
BMC Ophthalmol; 2022 Apr; 22(1):152. PubMed ID: 35366846
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.
Sun X; Liu Q; Tang X; Yao K; Li Y; Yang J; Zhang M; Yuan H; Zheng Y; Li W; Peng H
BMC Ophthalmol; 2022 Aug; 22(1):332. PubMed ID: 35932001
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma.
Egorov E; Ropo A;
Eur J Ophthalmol; 2009; 19(2):214-22. PubMed ID: 19253237
[TBL] [Abstract][Full Text] [Related]
14. Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability.
Oddone F
Expert Opin Drug Saf; 2022 Oct; 21(10):1259-1268. PubMed ID: 36250245
[TBL] [Abstract][Full Text] [Related]
15. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
Chabi A; Baranak C; Lupinacci R; Herring WJ
Int J Clin Pract; 2016 Jul; 70(7):577-86. PubMed ID: 27292765
[TBL] [Abstract][Full Text] [Related]
16. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
Kuwayama Y; Nomura A
Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
[TBL] [Abstract][Full Text] [Related]
17. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
[TBL] [Abstract][Full Text] [Related]
18. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
19. [Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204)].
Karlova EV; Petrov SY; Germanova VN
Vestn Oftalmol; 2020; 136(4):76-84. PubMed ID: 32779459
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.
Suzuki K; Otsuka N; Hizaki H; Hashimoto M; Kuwayama Y;
Adv Ther; 2018 Jun; 35(6):796-808. PubMed ID: 29873009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
